[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Unicycive Therapeutics Inc (UNCY)

Unicycive Therapeutics Inc (UNCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Unicycive Therapeutics Inc 1975 W. EL CAMINO REAL SUITE 204 MOUNTAIN VIEW CA 94040 USA

www.unicycive.com Employees: 22 P: 650-351-4495

Sector:

Medical

Description:

Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company's lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc. is based in LOS ALTOS, Calif.

Key Statistics

Overview:

Market Capitalization, $K 193,121
Enterprise Value, $K 163,921
Shares Outstanding, K 27,393
Float, K 25,741
% Float 93.97%
Short Interest, K 2,837
Short Float 10.36%
Days to Cover 3.77
Short Volume Ratio 0.65
% of Insider Shareholders 6.03%
% of Institutional Shareholders 40.42%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -26,560 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -12,820 K
EBIT, $ -29,960 K
EBITDA, $ -29,390 K

Growth:

1-Year Return 2.62%
3-Year Return -54.03%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.54 on 05/12/26
Next Earnings Date 08/13/26
Earnings Per Share ttm -2.27
EPS Growth vs. Prev Qtr 34.15%
EPS Growth vs. Prev Year -8.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 06/20/25

UNCY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -134.69%
Return-on-Assets % -84.51%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 5.08
Book Value/Share 1.41
Interest Coverage -378.43
60-Month Beta 1.73
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.